Led · Equity · Jan 2025

Aerin Medical is a privately held, venture-backed medical device company headquartered in Mountain View, California, focused on expanding access to relief for patients with chronic ENT conditions. Its products VivAer® (for nasal airway obstruction) and RhinAer® (for chronic rhinitis) leverage a proprietary temperature-controlled technology as alternatives to invasive surgery. The company reports that more than 150,000 patients have been treated with its products to date. Aerin said it will use recent financing to drive additional commercial expansion, invest in R&D, and further expand its clinical evidence portfolio. Management emphasized plans to deepen penetration in markets for nasal obstruction and chronic rhinitis. Financially, Aerin completed a $32.5 million equity financing and secured a debt facility to refinance existing debt and provide additional financial flexibility. Aerin Medical commercializes non-invasive, temperature-controlled radiofrequency treatments for chronic nasal conditions through its VivAer and RhinAer products. VivAer, launched in the U.S. in 2018, treats nasal airway obstruction (which the company cites as affecting 20 million Americans); RhinAer launched in 2020 for chronic rhinitis. More than 60,000 patients have been treated with Aerin products to date, and the company reported 10 new peer-reviewed clinical publications in the last year. Aerin is privately held and venture-backed, with U.S. offices in California and Texas. The company intends to use new financing to scale commercialization and expand market access to meet physician and patient demand. Aerin Medical develops non-invasive, office-based treatments for chronic nasal airway conditions. Its FDA-cleared VivAer® Stylus treats nasal airway obstruction and the RhinAer® Stylus treats chronic rhinitis using a proprietary temperature-controlled technology. The company provides tissue-sparing solutions for otolaryngologists (ENTs) to improve patient quality of life. Aerin is venture-backed and has offices in Sunnyvale, California and Austin, Texas. The company announced a leadership change with the appointment of Matt Brokaw as President and CEO. Proceeds from the financing will be used to accelerate commercial growth, support new clinical studies, and develop new products. Aerin Medical, led by CEO Fred Dinger and based in Austin, Texas, develops and commercializes minimally invasive treatments for nasal airway disorders. Its flagship product is the Vivaer Nasal Airway Remodeling System, a physician‑office procedure for treating nasal obstruction. The company focuses on improving patients' quality of life through disruptive, office‑based interventions. Financially, Aerin closed a $50M non‑dilutive term loan with CRG LP, receiving $35M at closing and up to $15M more in milestones. Approximately $16.5M of the proceeds were used to retire existing debt. The remaining funds are designated to accelerate sales and marketing reach and to support the launch of its next product. Aerin Medical is a medical device company that has developed a non-invasive treatment platform using low-power radiofrequency energy to remodel nasal soft tissues and address nasal congestion. The platform is designed for use in the physician’s office to treat underlying causes of nasal breathing disorders. Led by CEO Fred Dinger, Aerin operates offices in Austin, Texas; Sunnyvale, California; and Singapore. The company is backed by healthcare investors KCK Group and Targeted Technology. Aerin closed a $15M venture loan facility provided by Horizon Technology Finance Corporation. The company will use the proceeds for general working capital purposes.

Led · Series B · Sep 2023

Sonex Health specializes in ultrasound-guided treatment of common orthopedic syndromes affecting the extremities. Its proprietary devices enable surgeons to use real-time ultrasound guidance to visualize critical anatomy, reducing invasiveness and cost of care and enabling faster patient recovery. The company’s first commercial device, UltraGuideCTR, for carpal tunnel syndrome, received FDA clearance in 2019. Its second commercial device, UltraGuideTFR, designed to treat trigger finger, was released in 2022. Sonex intends to use proceeds from the financing to expand access to these commercially available devices and broaden patient treatment for CTS and TF. The company is led by president and CEO Bob Paulson.